General Information of Drug (ID: DMPQFTA)

Drug Name
Fucoxanthin
Synonyms
Fucoxanthin; UNII-06O0TC0VSM; CCRIS 4055; all-trans-Fucoxanthin; BRN 0073179; 06O0TC0VSM; beta,beta-Carotene, 3'-(acetyloxy)-6',7'-didehydro-5,6-epoxy-5,5',6,6',7,8-hexahydro-3,5'-dihydroxy-8-oxo-, (3S,3'S,5R,5'R,6S,6'R)-; (3S,5R,6S,3'S,5'R,6'R)-3,5'-dihydroxy-8-oxo-6',7'-didehydro-5,6-epoxy-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-3'-yl acetate; (3'S,5'R,6'R)-3'-acetoxy-5,6-epoxy-3,5'-dihydroxy-6',7'-didehydro-5,6,7,8,5',6'-hexahydro-beta,beta-caroten-8-one
Indication
Disease Entry ICD 11 Status REF
Metabolic syndrome x 5C50-5D2Z Phase 2 [1]
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
2
Molecular Weight 658.9
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 12
Hydrogen Bond Donor Count 2
Hydrogen Bond Acceptor Count 6
Chemical Identifiers
Formula
C42H58O6
IUPAC Name
NULL
Canonical SMILES
CC(=CC=CC=C(C)C=CC=C(C)C(=O)CC12C(CC(CC1(O2)C)O)(C)C)C=CC=C(C)C=C=C3C(CC(CC3(C)O)OC(=O)C)(C)C
InChI
InChI=1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23?,34-,35-,40+,41+,42-/m0/s1
InChIKey
SJWWTRQNNRNTPU-ABBNZJFMSA-N
Cross-matching ID
PubChem CID
5281239
ChEBI ID
CHEBI:5186
CAS Number
3351-86-8
DrugBank ID
DB15462
VARIDT ID
DR01663

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
NF-kappa-B inhibitor alpha (NFKBIA) TTSHAEB IKBA_HUMAN Inhibitor [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Gene/Protein Processing [4]
Amine oxidase B (MAOB) OTTDFM1O AOFB_HUMAN Gene/Protein Processing [4]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [5]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Gene/Protein Processing [6]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Protein Interaction/Cellular Processes [6]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Protein Interaction/Cellular Processes [6]
D(3) dopamine receptor (DRD3) OT0OFFKB DRD3_HUMAN Gene/Protein Processing [4]
D(4) dopamine receptor (DRD4) OTAJTO7N DRD4_HUMAN Gene/Protein Processing [4]
Gap junction alpha-1 protein (GJA1) OTT94MKL CXA1_HUMAN Gene/Protein Processing [7]
Gap junction beta-1 protein (GJB1) OT0F7OLN CXB1_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03613740) Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion. U.S. National Institutes of Health.
2 Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-B and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol. 2010 Dec 15;649(1-3):369-75.
3 Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
4 Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson's disease. Chem Biol Interact. 2019 Sep 1;310:108757. doi: 10.1016/j.cbi.2019.108757. Epub 2019 Jul 16.
5 Fucoxanthin prevents cell growth and induces apoptosis in endometrial cancer HEC-1A cells by the inhibition of the PI3K/Akt/mTOR pathway. J Biochem Mol Toxicol. 2022 Jun;36(6):e23027. doi: 10.1002/jbt.23027. Epub 2022 Mar 9.
6 Fucoxanthin induces apoptosis in human leukemia HL-60 cells through a ROS-mediated Bcl-xL pathway. Toxicol In Vitro. 2010 Sep;24(6):1648-54. doi: 10.1016/j.tiv.2010.05.023. Epub 2010 Jun 8.
7 Inhibition of proliferation of a hepatoma cell line by fucoxanthin in relation to cell cycle arrest and enhanced gap junctional intercellular communication. Chem Biol Interact. 2009 Dec 10;182(2-3):165-72. doi: 10.1016/j.cbi.2009.08.017. Epub 2009 Sep 6.